Printer Friendly

LUNAR ANNOUNCES THAT ONE-ALPHA D2 WAS EFFECTIVE

 DEPRENYL RESEARCH LIMITED AND BONE HEALTH INC. IN NEGOTIATIONS TO
 SIGNIFICANTLY INCREASE THEIR STAKE IN WORLD RIGHTS TO ONE-ALPHA D2
 TORONTO, Jan. 4 /PRNewswire/ -- Deprenyl Research Limited ("Deprenyl") (TSE: DEP; NASDAQ: DEPLF) and Bone Health Inc. ( Bone Health''), its wholly owned subsidiary, today announced that they have entered into negotiations with Lunar Corp. ( Lunar'') (NASDAQ: LUNR) and its subsidiary Bone Care International ( Bone Care'') to significantly increase their combined stake in te world rights to one- alpha D2.
 Bone Health has recently completed its examination of the Lunar re-analysis of the final data from the clinical studies carried out as part of the Creighton University study of one-alpha D2 in women with osteoporosis. Patients were excluded from the analysis if blood and urinalysis showed that they did not take the drug or that they had evidence of a coexisting metabolic disorder in addition to osteoporosis. Creighton's analysis of its own data has not been completed.
 Based on this analysis and on the previously available research results, Bone Health believes that, contrary to the assessment of the preliminary data, this analysis of the final data established that the drug had a significantly positive effect on spinal bone mineral density and on biochemical responses of women with osteoporosis who took the drug and who did not suffer from any coexisting metabolic disorder. The spinal bone scan corrections were independently confirmed by the same analysts who carried out the analysis of the preliminary data. Consultations were carried out and advice received from experts in bone metabolism who were not associated with any of the parties.
 As a result, Deprenyl and Bone Health have entered into negotiations with Lunar(1) to significantly increase their combined net interest in the world rights to one-alpha D2. (Deprenyl already owns 14 percent of Bone Care and therefore has 14 percent of those rights.) The proceeds of the payments will be used by Bone Care exclusively for the funding of advanced placebo-controlled multi-centre clinical trials of one- alpha D2. The proposed transaction would be subject to further due diligence, regulatory approval, and Bone Health realizing proceeds of at least CDN $4,300,000 from the exercise of warrants of Bone Health prior to May 7, 1993.
 All of the parties acting together will actively seek other development partners in exchange for all or part of the world rights to one-alpha D2.
 Deprenyl Research Limited is a Canadian Pharmaceutical Company with several development stage affiliates. It develops and markets pharmaceutical agents for neurologic diseases, chronic diseases and diseases of aging and dermatology.
 (1) Lunar reported in a press release of Dec. 31, 1992 that despite the positive results of their re-analysis, Takeda Industries, Ltd. would be surrending all of its rights to one-alpha D2 for Japan, Taiwan and South Korea to Lunar's subsidiary, Bone Care, after March 2, 1993.
 -0- 1/4/93
 /CONTACT: Martin Barkin, MD, President & CEO or Deborah Worobec, Investor Relations, 416-537-4372 (416-537-1653 FAX); both of Deprenyl Research, or (U.S. Contact) Jim Tolan, senior vice president of O'Connor Biro & Associates, 708-498-2284 (708-498-3144 FAX)/
 (DEPLF LUNR)


CO: Deprenyl Research Limited; Bone Health Inc. ST: Ontario IN: MTC SU:

SB -- NY013 -- 1169 01/04/93 08:46 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 4, 1993
Words:531
Previous Article:MICROPROBE RECEIVES PERMISSION TO MARKET ID SYSTEM FOR PERIODONTAL DISEASE-ASSOCIATED ORGANISMS IN 11 COUNTRIES
Next Article:PARENTS TODAY STRESS BEING WITH CHILDREN MORE THAN THEY SAY THEIR PARENTS DID
Topics:


Related Articles
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
BONE HEALTH INC. & DEPRENYL RESEARCH LIMITED ANNOUNCE SMITHKLINE BEECHAM HAS TRANSFERRED BACK TO LUNAR CORP. ALL ITS RIGHTS TO ONE-ALPHA D-2
DEPRENYL RESEARCH LTD. RECEIVES NOTIFICATION FROM LUNAR OF TAKEDA'S INTENT TO TERMINATE LICENSE AGREEMENT
BONE HEALTH INC.: INDEPENDENT ANALYSIS OF ONE-ALPHA D2 TO BE COMPLETED
BONE HEALTH INC.: INDEPENDENT ANALYSIS OF ONE-ALPHA D2 TO BE COMPLETED
BONE HEALTH INC. WARRANTS EXTENDED TO SEPT. 30, 1993
Lower Prices in the D2-Fun Tariff This Year.
Improved matrix-assisted laser desorption/ionization time-of-flight mass spectrometric method for identification of amino acid O-glycosides in...
Women's health update: vitamin D2 vs. vitamin D3: is one form better than the other?

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters